Derek Ruff, UC San Diego Health (IMAGE) University of California - San Diego Caption Derek Ruff enrolled in a phase I clinical trial at Moores Cancer Center at UC San Diego Health of a new iPSC-derived natural killer cell cancer immunotherapy developed by Fate Therapeutics that received U.S. Food and Drug Administration approval in November 2018. Credit UC San Diego Health Usage Restrictions Use photo credit as indicated License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.